The continuous global spread of highly pathogenic avian influenza (HPAI) H5N1 viruses in avian species and humans poses a significant threat to public health. The recent outbreak of highly contagious novel influenza A H1N1 virus in Mexico and North America and its quick spread through direct transmission between humans deepen the fear of an imminent pandemic outbreak [1] . Under these circumstances, vaccines that can
The continuous global spread of highly pathogenic avian influenza (HPAI) H5N1 viruses in avian species and humans poses a significant threat to public health. The recent outbreak of highly contagious novel influenza A H1N1 virus in Mexico and North America and its quick spread through direct transmission between humans deepen the fear of an imminent pandemic outbreak [1] . Under these circumstances, vaccines that can confer protection against viruses within the same subtype (subtype-specific immunity) or between different subtypes (heterosubtypic immunity) would be highly desirable. Inactivated influenza vaccines delivered intramuscularly can efficiently elicit neutralizing antibodies that are, however, generally restricted to circulating strains or viruses that are antigenically closely related. Unlike inactivated influenza vaccines, live attenuated vaccines are administered intranasally and are capable of inducing mucosal immunity and preventing virus entry and subsequent replication in the respiratory tract [2, 3] . In addition to inducing neutralizing antibodies against circulating strains, live attenuated vaccines can also elicit viral epitope-specific cytotoxic CD8 + T lymphocytes and confer heterosubtypic immunity [4] [5] [6] .
We have long been interested in the roles of the viral M1 gene in the pathogenesis and growth of influenza viruses, especially the multibasic motif 101RKLKR105 of M1 protein. The RKLKR motif is involved in the [9, 10] , M(NLS-88R) (present study), and mu-rWSN [12] were generated by reverse genetics with different point mutations in corresponding internal genes. -, Amino acid on this position remains unchanged as wt-WSN.
nuclear localization signal (NLS) and in viral RNA and ribonucleoprotein (RNP) binding [7, 8] . Using wild-type A/WSN/ 33 (wt-WSN, H1N1) as a model, we previously have shown that double point mutations in the RKLKR motif (R101S-R105S) impair viral replication in vitro and result in temperature sensitivity (ts) and attenuation [9, 10] . In the present study, we demonstrated that an additional mutation (G88R) in the adjacent region of the RKLKR domain could restore viral replication to a level similar to that of wt-WSN in vitro but that it still retained the attenuation phenotype in mice. The vaccine potential of the new WSN M1 mutant, designated "M(NLS-88R)," was further explored.
MATERIALS AND METHODS
Viruses. The full-length matrix (M) complementary DNA of mouse-adapted wt-WSN (H1N1) was cloned, and 3 point mutations (G88R, R101S, and R105S) in the RKLKR motif and its adjacent region of M gene were incorporated into the plasmid pPol I-WSN-M (a gift from Y. Kawaoka, University of Wisconsin-Madison, Madison), as described elsewhere [9, 10] . The pPol I-WSN-M expressing the mutated M gene was then mixed with the plasmids expressing the other 7 viral genes of wt-WSN (0.5 mg/plasmid), including pHW181-PB2, pHW182-PB1, pHW183-PA, pHW184-HA, pHW185-NP, pHW186-NA, and pHW188-NS (gifts from R. Webster, St. Jude Children's Research Hospital, Memphis, Tennessee), followed by incubation with TransIT LT-1 (Panvera) to form transfection complex. The plasmid-transfection complex mixture was delivered into cocultured 293T and Madin-Darby canine kidney (MDCK) cells [11] . Six h later, the plasmid-transfection mixture was replaced by fresh Opti-MEM I medium (Invitrogen) containing 0.5 mg/mL L-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK)-trypsin. The rescued M1 mutant was designated "M(NLS-88R)" (H1N1) ( Table 1) . wt-WSN was similarly derived by reverse genetics. mu-rWSN (H1N1), a cold-adapted (ca) WSN mutant that has been reported elsewhere [12] , contained the 5 key mutations in the PB1 (K391E, E581G, and A661T), PB2 (N265S), and nucleoprotein (NP) (D34G) genes that contributed to ts, ca, and attenuation phenotypes (Table  1 ) [13] . All the mutants were confirmed by DNA sequencing (Center for Biologics Evaluation and Research/Food and Drug Administration [CBER/FDA] core facility, Bethesda, Maryland). Mouse lung-amplified A/Philippines/2/82/X-79 (H3N2) was provided by S. Epstein (CBER/FDA). All virus stocks used in the present study, including the WSN double mutant R101S-R105S (H1N1) [9, 10] , mouse-adapted A/FM/1/47-MA (FM, H1N1), and HPAI A/Vietnam/1203/2004 (H5N1), were propagated in the allantoic cavities of 9-to 11-day-old embryonated hen's eggs at 33ЊC or 37ЊC (for HPAI A/Vietnam/1203/2004), and then were aliquoted and stored at Ϫ70ЊC until use. Virus infectivity was determined by plaque assay using MDCK cells or 50% egg infectious dose (EID 50 ), as described elsewhere [14, 15] .
In vitro and in vivo characterization of M(NLS-88R).
The ts phenotype of wt-WSN, M(NLS-88R), and R101S-R105S was determined by comparing viral replication in MDCK cells at 33ЊC versus 39ЊC. Viruses that had у2 logs of reduction from viral titers at 39ЊC to those at 33ЊC were considered to be of the ts phenotype.
Four-to 6-week-old specific-pathogen-free female BALB/c mice (Taconic Farm) were inoculated intranasally with M(NLS-88R) at a dose range of -plaque-forming units (pfu) per 4 6 10 10 50 mL of phosphate-buffered saline (PBS) per mouse under light isofluorane anesthesia. Body weight was monitored for up to 2 weeks after infection. A separate set of mice that were infected with M(NLS-88R) at pfu per 50 mL of PBS 4 5 ϫ 10 per mouse were euthanized on days 2, 4, and 7 after infection. Lungs and brains were harvested, homogenized, and then titrated on 100% confluent MDCK cells by plaque assay. Mice infected with wt-WSN given at the same dose served as a control.
Immunogenicity of M(NLS-88R).
Unless otherwise specified, groups of 4-to 6-week-old female BALB/c mice were inoculated intranasally with a single dose of M(NLS-88R) at pfu per 50 mL of PBS per mouse. Serum samples were 4 5 ϫ 10 collected by tail or orbital plexus bleeding at 4 weeks after infection or immediately before challenges, and they were stored at Ϫ20ЊC until use. Aliquots of hyperimmune serum were pretreated with receptor-destroying enzyme (Denka-Seiken) before hemagglutination inhibition (HAI) assay was performed using 4 hemagglutinin (HA) units of virus and 0.5% turkey red blood cells, for H1N1 and H3N2 viruses, or 1% horse red blood cells, for H5N1 virus [16] . H1N1 virus-or H3N2 virus-specific neutralizing antibody activity was determined using a method previously described elsewhere, with some modifications [6] . In brief, serum samples serially diluted in 10-fold increments were incubated with 100 pfu of live wt virus in equal volumes at room temperature for 60 min. The remaining infectivity of the virus-serum mixtures was detected by plaque assay and expressed as a percentage of plaque reduction from the normal serum-treated (1:50 dilution) virus mixtures. H5N1-specific neutralizing antibody titers were assessed by microneutralization assay. In brief, hyperimmune serum samples were serially diluted in 2-fold increments starting at a 1:10 dilution and were incubated with an equal volume of 1 hundred 50% tissue culture infectious doses (TCID 50 ) of HPAI A/Vietnam/1203/2004 at room temperature for 60 min. The virus-serum mixtures were then incubated with MDCK cells/well in 96-well plates at 33ЊC overnight. The 4 10 residual infectivity of H5N1 virus was measured using an NPspecific mouse monoclonal antibody, followed by fluorescein isothiocyanate-labeled secondary antibody. Protection against homologous and heterologous challenges. Animal infection studies using mouse-adapted influenza viruses or human H5N1 vaccine strains were performed in a biosafety level-2 facility at CBER/FDA, in accordance with the protocols approved by the animal care and use committee of the CBER/ FDA. Mice immunized with M(NLS-88R) were challenged intranasally with wt-WSN (H1N1), FM (H1N1), A/Philippines/ 2/82/X-79 (H3N2), or the human H5N1 vaccine strain A/Vietnam/1203/2004/X-PR8 at 4 weeks or 2-6 months later. Morbidity (as measured by weight loss) and mortality were monitored daily for up to 2 weeks after infection. Lungs from challenged mice were harvested on day 3 after infection, homogenized, and titrated on MDCK cells by plaque assay. In a separate experiment, mice immunized with M(NLS-88R) were depleted of CD8 or CD4 T cells by intraperitoneal injection of 2 doses of anti-CD8 (Clone 53-6.7; eBioscience) or anti-CD4 (Clone RM4-5; eBioscience) at 0.5 mg/dose one day before and one day after wt-WSN challenge, as described elsewhere [5] . The depletion efficiency was confirmed by flow cytometry. Mice injected with isotype-matched rat immunoglobulin (Ig) G2a (eBioscience) served as control subjects.
The 5 ϫ 10 5 ϫ 10 virus titers were determined by plaque assay performed on day 3 after infection (3 mice/group) (C). The lower detection limit is denoted by the dashed horizontal line. ** and *** , by unpaired Student's t test performed on log-transformed data.
for 14 days for morbidity and mortality. Four mice from each group were euthanized on day 6 after infection. Lungs, noses, and brains were collected, and virus titers were determined by EID 50 , as described elsewhere [3] . Major histocompatibility class class I tetramer staining and flow cytometry. Phycoerythrin (PE)-labeled NP 147-155 -specific major histocompatibility class class I tetramer was produced by the National Institutes of Health Tetramer Core Facility and Beckman-Coulter. Lungs harvested from M(NLS-88R)-infected mice on day 7 after infection were minced and digested in the presence of collagenase type II (300 U/mL) and deoxyribonuclease I at 37ЊC for 1 h. Single suspended lung cells were then stained with PE-labeled NP 147-155 -specific major histocompatibility class class I tetramer and counterstained with fluorescein isothiocyanate-labeled CD8 (Clontech) and PE-cyanine dye 5 (Cy5)-labeled CD3 (BD Biosciences). The acquisition was completed in a FACSCanto II cytometer (BD Biosciences), and the data were analyzed using FlowJo software (Tree Star).
Adoptive transfer experiments. Hyperimmune serum samples obtained from M(NLS-88R)-immunized mice were pooled and injected intravenously into naive BALB/c mice at 100 mL/ mouse. Single-splenocyte suspensions free of red blood cells were prepared from mice immunized with a single dose of M(NLS-88R) (H1N1), and 2-cells/mouse were adop-7 4 ϫ 10 tively transferred intravenously into naive BALB/c hosts. Twenty-four h later, the recipient mice were challenged with wt-WSN (H1N1) or A/Philippines/2/82/X-79 (H3N2). Mortality was monitored for up to 28 days after infection. In some experiments, a separate set of naive mice were included that received the same volume or number of mu-rWSN (H1N1; pfu given intranasally per mouse)-induced hyperim- Comparisons between experimental groups were evaluated using unpaired Student's t test with a 2-tailed P value. Statistical significance was defined by . P ! .05
RESULTS

In vitro and in vivo characterization of M(NLS-88R).
Using wt-WSN as the parent strain, we previously have shown that substitution of arginine with serine at amino acid positions 101 and 105 of the RKLKR motif reduced viral replication in MDCK cells and resulted in ts in vitro and attenuation in vivo [10] . However, the rescue process of this R101S-R105S double mutant was quite tricky, and the rescued R101S-R105S was unstable, with some phenotypes altered after multiple passages in embryonated eggs (data not shown). Hence, we introduced a third mutation at position 88, with an arginine substituted for a glycine, which was a compensatory mutation that emerged during the attempts of rescuing R10S-R105S; the resultant triple mutant was designated "M(NLS-88R)" (Table 1) . Unlike an early passage of the double mutant R101S-R105S that had у2 logs of reduction in viral titers when the temperature increased from 33ЊC to 39ЊC, the M(NLS-88R) replicated equally efficiently at both temperatures ( Figure 1A ), indicating that this new mutant was not ts. M(NLS-88R) also demonstrated an improved replication potential, compared with the double mutant R101S-R105S, with a growth curve similar to that of wt-WSN in vitro ( Figure 1B) . Moreover, M(NLS-88R) remained genetically and phenotypically stable after 115 passages in MDCK cells and/or embryonated eggs (data not shown).
Interestingly, intranasal administration of M(NLS-88R) mutant at a dose range of -pfu/mouse resulted in no mor- 4 6 10 10 bidity or mortality ( Figure 1C and data not shown), indicating an attenuated phenotype with an MLD 50 1 pfu/mouse. 6 1 ϫ 10
Conversely, wt-WSN at a dose of pfu/mouse caused a 4 5 ϫ 10 mortality rate of 100% among infected mice by day 7 after infection ( Figure 1C ). The attenuation of M(NLS-88R) in mice was further confirmed by significant reductions in lung viral replication, compared with wt-WSN ( Figure 1D ). By day 7 after infection, M(NLS-88R) was completely cleared from the respiratory tract (with viral titers below the detection limit), whereas wt-WSN virus still sustained a significantly high level of replication in mouse lungs at the same time ( Figure 1D ). Systemic spread of virus to the brain was not detected with either M(NLS-88R) or wt-WSN (data not shown), indicating that replication of these viruses was restricted to the murine respiratory tract.
Immunogenicity of M(NLS-88R).
A single intranasal administration of M(NLS-88R) elicited a strong antibody response against the wt-WSN virus 4 weeks later, with a geometric mean HAI titer 1380 (Figure 2A ). Even at 1:5000 dilution, the M(NLS-88R)-induced hyperimmune serum samples still yielded 140% plaque reduction than did naive mouse serumtreated control, exhibiting strong neutralizing activity toward wt-WSN ( Figure 2B ). Moreover, M(NLS-88R) immunization completely prevented pulmonary replication of wt-WSN in challenged mice on day 3 after infection (below the limit of Protection against homologous subtype (H1N1) challenges. A single dose of M(NLS-88R) not only fully protected mice from morbidity or mortality after a lethal wt-WSN challenge ( Figure 3A ) but also fully protected mice from lethal infection with an antigenically distant FM H1N1 virus ( Figure 3B ). Depletion of the CD4 or CD8 T cell population had no effect on the body weight and survival of M(NLS-88R)-primed mice after a lethal wt-WSN challenge (data not shown), suggesting that humoral response but not T cell immunity may be responsible for M(NLS-88R)-induced homologous protection. To confirm this finding, we conducted transfer studies using M(NLS-88R)-induced hyperimmune serum and splenocytes. As shown in Figure 3C , passive transfer of M(NLS-88R)-induced hyperimmune serum samples protected the recipient mice from lethal challenge with wt-WSN, except for transient morbidity that occurred on day 3 after infection. However, the mice receiving M(NLS-88R)-primed splenocytes continued to lose weight upon challenge, and all died on day 10 after infection ( Figure  3C ). These results further suggested that protection against homologous virus was mainly antibody dependent. In a separate experiment involving challenge with 1 MLD 50 of wt-WSN, mice receiving M(NLS-88R)-primed splenocytes showed significant morbidity similar to that among naive mice, but they eventually all survived ( Figure 3D ); this outcome indicated that cell-mediated immunity was still beneficial, but apparently it had a relatively limited role in homologous protection. Figure 4A ). M(NLS-88R)-primed mice also exhibited significantly reduced pulmonary replication of A/Philippines/2/82/X-79 (H3N2) on day 3 after infection, compared with naive mice ( ) ( Figure 4B ). P ! .01 A/Vietnam/1203/2004/X-PR8 (H5N1) is a human vaccine strain that contains a multibasic amino acid motif-deleted H5 HA and wt N1 genes from the HPAI A/Vietnam/1203/2004 and 6 internal genes from PR8. This reassortant is attenuated in ferrets and chickens but is lethal to mice at high infectious doses. As shown in Figure 4C , all M(NLS-88R)-vaccinated mice, but not naive mice, survived a lethal challenge with this reassortant virus 2 months after initial immunization. When chal- 
Protection against heterologous viruses, including HPAI
DISCUSSION
The RKLKR motif of M1 protein is involved in both RNA and RNP binding and nuclear localization signal of influenza viruses [7, 8] . In addition to 2 previously reported mutations (R101S and R105S) in the RKLKR motif, a third mutation (G88R) was introduced into the nearby region in the present study; this not only alleviated the rescue process, it also improved the stability of the resultant mutant M(NLS-88R). More importantly, the additional mutation at position 88 (G88R) of the M1 protein restored viral replication to the wt level in vitro, suggesting that the RKLKR motif of M1 protein and its adjacent region are both involved in controlling viral replication. However, the M(NLS-88R) mutant still exhibited significantly reduced pathogenesis in vivo and was attenuated in mice even at high infectious doses (eg, pfu/mouse). An H5N1 mutant with an 6 10 M2 cytomplasmic tail deletion was also reported to have reduced pathogenesis in mice, despite a growth rate similar to that of the wt strain in vitro [17] . These results suggest that in vitro replication apparently does not always correlate with viral lethality in vivo. In addition, M(NLS-88R)-immunized mice were protected from lethal infections with both homologous and heterologous influenza A viruses, including HPAI A/Vietnam/1203/2004 (H5N1), after a single vaccination dose. All of these findings suggest that modifying the RKLKR motif and its adjacent region of the viral M1 gene could be a potential approach to attenuating wt influenza A viruses for vaccine development. However, modifying only the M1 gene is insufficient to warrant the safe application of resultant live attenuated vaccine candidates in humans. This can be improved by incorporating additional mutations into the other internal genes [13, 16] , such as NP, PB1, and PB2, that are currently under investigation.
Passive transfer of M(NLS-88R)-specific hyperimmune serum completely protected the recipient mice against lethal wt-WSN infection, clearly suggesting that an optimal antibody response is crucial for homologous protection. We further demonstrated that cell-mediated immunity could provide moderate protection against homologous viruses, although it is unable to prevent infection as efficiently as an antigenically matched antibody response. This finding suggests that preexisting cellular immunity could be beneficial in "buying" time for the host to mount a sufficient humoral response against influenza infections, even if preselected vaccine strains do not exactly match the circulating viruses. In this regard, live attenuated vaccines may be advantageous over inactivated vaccines, because the former are likely to be better at eliciting cellular immunity.
In addition, infection with M(NLS-88R) or wt-WSN yielded no detectable antibodies against H3N2 or H5N1 viruses, by HAI or microneutralization assay, or cross-reactive antibodies to recombinant H3 HA or H5 HA, by enzyme-linked immunosorbent assay (ELISA) (data not shown). However, M(NLS-88R)-primed mice were still protected from subsequent lethal challenges with heterologous influenza A viruses, which was partially attributed to M(NLS-88R)-induced humoral response. This could be the result of insensitivity of the current detection methods to measure the minute portion of crucial antibodies masked by nonspecific immunoglobulin (Ig) G or serum proteins or the fact that mechanisms other than HA-or NA-specific IgG or IgA have not yet been identified. Early studies suggest that antibodies to conserved viral internal proteins, such as NP or M1, do not play a significant role in protection in vivo [18] [19] [20] [21] . However, a recent study reported that NP-specific nonneutralizing antibodies could significantly reduce morbidity, lower viral titers, and transfer protection to naive mice [22] . A separate study conducted by the same group also suggested that nonneutralizing antibodies conferred heterosubtypic protection only in the presence of memory T cells [23] . The transferred heterosubtypic protection provided by M(NLS-88R)-specific hyperimmune serum is also unlikely because of M2-specific nonneutralizing antibodies, because M2 is a small transmembrane protein existing in a minimal quantity in viral particles, and because natural infection induces a poor antibody response to M2 [7, [23] [24] [25] . Exposure to different influenza A subtypes can also induce cross-reactive T cells specific for viral epitopes that are shared by different viruses [5, [26] [27] [28] [29] . Epitopespecific CD8 + T cells can facilitate viral clearance and contribute to heterosubtypic protection against H5N1 viruses [29, 30] . Vaccination with M(NLS-88R) also yielded a considerable level of NP 147-155 -specific CD8 + T cells, but adoptive transfer of M(NLS-88R)-induced splenocytes cells was insufficient to fully protect recipient mice against the heterologous challenge. This is perhaps not surprising, because B cells-but not T cellsare vital for heterosubtypic protection, and memory T cells are less efficient in providing cross-protection in the absence of B cells [23, 30] . Taken together, our results suggest that modifying the RKLKR motif of the M1 gene and its adjacent region could be a potential approach to attenuating wt influenza viruses for vaccine development with broad cross-protection.
